Skip to main content

Advertisement

SpringerLink
Log in

Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme

  • Clinical-Patient Studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Purpose

The prognosis for patients with glioblastoma multiforme remains poor. Phase II studies, meta-analyses and a phase III study show that concurrent chemoradiotherapy has an advantage over irradiation alone. In this study the effectiveness of concurrent chemoradiotherapy with Topotecan and an adjuvant chemotherapy with Topotecan was investigated.

Patients and method

Forty-two patients with predominantly unfavourable prognosis factors were included in the study and treated as follows: hyperfractionated accelerated radiotherapy (2×1.75Gy to 45.5 + 12.25 Gy (RP)) with a concurrent, continuous infusion of Topotecan (0.5 mg/m2/d, days 1–21). On day 28 the adjuvant chemotherapy (three courses) was begun according to the same scheme.

Result

Haematological toxicities were 13/42 (30%) grade III leucopenia, 2/42 (4%) grade IV, as well as 5/42 (10%) grade III thrombopenias and 1/42 (2%) grade IV. 30/42 (71%) patients showed improvement or stabilisation of an existing neurological symptomatic complex. The median time to progression was 7.2 (+/− 0.8) months, the median total survival was 10 (+/− 1.2) months, the 2 year survival rate 4.7 (+/− 0.3)%. Prognostic factors were age, surgical radicality, performance status and the tumour volume before therapy.

Summary

Concurrent chemoradiotherapy and an adjuvant chemotherapy with Topotecan is feasible at acceptable toxicity levels also for patients with a moderate performance status. The patients benefit from the improvement of the clinical symptomatic complex and, even with unfavourable prognosis factors, have a higher median survival in comparison to data published on similar groups of patients given only radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bamberg M, Hess CFRadiation therapy of malignant gliomas Onkologie 15: 178–189, 1992

    Google Scholar 

  2. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, Kiessling M Amplification of epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma Int J Cancer 56:72–77, 1994

    Article  PubMed  CAS  Google Scholar 

  3. Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J, Branguer D, Hoang-Xuan K, Moktari K, Peragut JC, Martin PM, Grisoli F Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations Cancer 100:2208–2014, 2004

    Article  PubMed  CAS  Google Scholar 

  4. Gil-Salu JL, Roman P, Benitez E, Maestro E, Perez-Requena J, Lopez-Escobar M Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme Neurocirugia 15:144–150; 2004

    PubMed  CAS  Google Scholar 

  5. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial J Neurosurg 49: 333–343, 1978

    PubMed  CAS  Google Scholar 

  6. Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M Radiotherapy for high-grade gliomas does altered fractionation improve the outcome? Strahlenther Onkol 180:401–407, 2004

    Article  PubMed  Google Scholar 

  7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn M, Brandes AA, Cairncross G, Lacombe D, Mirimanoff RO Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group Abstract Proc Am Soc Clin Oncol 22:14S (Abstr 2), 2004

    Google Scholar 

  8. Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum (II)-sensitive and – resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo Int J Cancer 53: 118–123, 1993

    Article  PubMed  CAS  Google Scholar 

  9. Chastagner P, Kozin SV, Taghian A Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and Glioblastoma multiforme xenografts in nude mice Int J Radiat Oncol Biol Phys 50:777–782, 2001

    Article  PubMed  CAS  Google Scholar 

  10. Rave-Frank M, Glomme S, Hertig J, Weiss E, Pradier O, Hess CF, Virsik-Kopp P, Schmidberger H Combined effect of Topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro Strahlenther Onkol 178:497–503, 2002

    Article  PubMed  Google Scholar 

  11. Grabenbauer GG, Anders K, Fietkau RJ, Klautke G, Feldmann HJ, Weiser S, Staab HJ, Krauseneck P, Sauer R Prolonged infusional Topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma—a phase I study J Neurooncol 60:269–275, 2002

    Article  PubMed  Google Scholar 

  12. Celerier D, Maire JP, Caudry M, Guerin J, Reboul J Interest of clinical classification in prognosis and therapeutics of multiform glioblastomas of adult patients Sem Hop 57:236–239, 1981

    PubMed  CAS  Google Scholar 

  13. Anders K, Grabenbauer GG, Schuchardt U, Fahlbusch R, Fietkau R, Sauer R, Krauseneck P Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma J Neurooncol 48: 63–73, 2000

    Article  PubMed  CAS  Google Scholar 

  14. Barker FG 2nd, Chang SM, Larson DA, Sneed PK, Wara WM, Wilson CB, Prados MD Age and radiation response in glioblastoma multiforme Neurosurgery 49: 1288–1297, 2001

    Article  PubMed  Google Scholar 

  15. Stark AM, Nabavi A, Mehdorn HM, Blomer U Glioblastoma multiforme-report of 267 cases treated at a single institution Surg Neurol 63: 162–169, 2005

    Article  PubMed  Google Scholar 

  16. Jeremic B, Shibamoto Y, Grujicic D, Stojanovic M, Biljana M, Nikolic N, Dagovic A, Aleksandrovic J Concurrent accelerated hyperfractionated radiation therapy, carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study J Neurooncol 51: 133–141, 2001

    Article  PubMed  CAS  Google Scholar 

  17. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20: 1375–1382, 2002

    Article  PubMed  CAS  Google Scholar 

  18. Miller PJ, Hassanein RS, Shanker PG Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors Int J Radiat Oncol Biol Phys 19:275–280, 1990

    PubMed  CAS  Google Scholar 

  19. Ganju V, Jenkins RB, O`Fallon JR, Scheithauser BW, Ransom DT, Katzmann JA, Kimmel DW Prognostic factors in gliomas Cancer 74:920–927, 1994

    Article  PubMed  CAS  Google Scholar 

  20. Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection J Neurooncol 52:161–171, 2001

    Article  PubMed  CAS  Google Scholar 

  21. Jeremic B, Milicic B, Grujicic D, Samardzic M, Antunovic V, Dagovic A, Aleksandrovic J, Stojanovic M Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with combined modality approach J Cancer Res Clin Oncol 129: 477–484, 2003

    Article  PubMed  Google Scholar 

  22. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R A multivariate analysis of 416 patients with glioblastoma multiforme, extent of resection, and survival J Neurosurg 95: 190–198, 2001

    Article  PubMed  CAS  Google Scholar 

  23. Shibamoto Y, Nishimura Y, Tsutsui K, Sasai K, Takahashi M, Abe M Comparison of accelerated hyperfractionated radiotherapy and conventional radiotherapy for supratentorial malignant glioma Jpn J Clin Oncol 27: 31–36, 1997

    Article  PubMed  CAS  Google Scholar 

  24. Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme Int J Radiat Oncol Biol Phys 49:71–77, 2001

    Article  PubMed  CAS  Google Scholar 

  25. Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial Anticancer Res 23: 5159–5164, 2003

    PubMed  CAS  Google Scholar 

  26. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted emozolomide schedules Br J Cancer 88: 1004–1011, 2003

    Article  PubMed  CAS  Google Scholar 

  27. Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients J Neurooncol 66: 203–208, 2004

    Article  PubMed  Google Scholar 

  28. Odrazka K, Petera J, Kohlova T, Dolezel M, Vaculikova M, Zouhar M, Malek V, Hobza V, Latr I, Nemecek S, Sercl M, Ryska P, Blaha M Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma Strahlenther Onkol 179: 615–619, 2003

    Article  PubMed  Google Scholar 

  29. Lally BE, Colasanto JM, Fischer JJ, Knisely JP Is there an optimal hemoglobin level for patients with glioblastoma multiforme? Cancer J 10: 391–396, 2004

    Article  PubMed  Google Scholar 

  30. Heesters M, Molenaar W, Go GK Radiotherapy in supratentorial gliomas. A study of 821 cases Strahlenther Onkol 179: 606–614, 2003

    Article  PubMed  Google Scholar 

  31. Glioma Meta-analysis Trialists (GMT) Group Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359: 1011–1018, 2002

    Article  Google Scholar 

  32. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu JI, Oka K, Ishimaru Y, Ushio Y Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme Cancer Res 63: 6962–6970, 2003

    PubMed  CAS  Google Scholar 

  33. Eller JL, Longo SL, Kyle MM, Bassano D, Hicklin DJ, Canute GW Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo Neurosurgery 56: 155–162, 2005

    PubMed  Google Scholar 

  34. Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus JU, Weber KJ, Huber PE Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhiition (SU5416) in human endothelial and tumor cells Int J Radiat Oncol Biol Phys 60: 1220–1232, 2004

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiotherapy, University of Rostock, Südring 75, 18059, Rostock, Germany

    G. Klautke, I. Bombor & R. Fietkau

  2. Department of Neurosurgery, University Hospital, Rostock, Germany

    M. Schütze & J. Piek

  3. Department of Neurology, University Hospital, Rostock, Germany

    R. Benecke

Authors
  1. G. Klautke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Schütze
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Bombor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Benecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Piek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Fietkau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Klautke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klautke, G., Schütze, M., Bombor, I. et al. Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme. J Neurooncol 77, 199–205 (2006). https://doi.org/10.1007/s11060-005-9028-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-005-9028-6

Keywords

Search

Navigation